Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-07-07

Clinical Trial Update: Ataluren for Nonsense Mutation Methylmalonic Acidemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of ataluren for nonsense mutation-induced methylmalonic acidemia has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ataluren (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Amino Acid Metabolism, Inborn Errors | Phase 2 | Status: TERMINATED | Results posted: 2020-07-07